

ASX Announcement

Investor Webinar Presentation

Sydney Australia, 15 April 2025: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (the **Company** or **Recce**), is pleased to announce a live online webinar.

The webinar will be held online via Zoom at **2:00pm AEST on Tuesday, 22 April 2025**. The webinar will be recorded for those who cannot attend.

To attend the webinar, register using the link below:

https://us02web.zoom.us/webinar/register/WN_KmQn9TeLQEmxR7c4ZQhORA

During the webinar, Managing Director and Chief Executive Officer, Mr James Graham, Executive Chairman, Dr John Prendergast, and Chief Medical Adviser and Non-Executive Director, Dr Alan W Dunton will provide an update on recent clinical activities, the outlook for upcoming Phase 3 clinical trials and details of the recently announced AUD ~\$15.8 million Placement and Entitlement Offer that will support the upcoming clinical activities as Recce progresses towards commercialisation in 2026.

A copy of the presentation slides was released via the ASX and Company website on 10 April 2025. The slides can be accessed [here](#).

A full recording of the webinar will be made available via the Recce website following the event.

This announcement has been approved for release by the Recce Pharmaceuticals Board.



ASX: RCE, **FSE:** R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T** +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA